Mitochondrial Derived Reactive Oxygen Species on Cardiovascular Health in Chronic Obstructive Pulmonary Disease (COPD)
Reason given: Funding was inconsistent and the Post-Doc left before the project ended
Key facts
- Where
- Richmond, United StatesSee the site
- Phase
- Early phase 1
Where in United States
- Virginia Commonwealth UniversityRichmond, United StatesNo longer taking part
Trial details
- Who runs it
- Virginia Commonwealth University
- Trial code
- NCT05605548
- Record updated
- 27 February 2025
- Original description
Cardiovascular health is a critical problem in patients with chronic obstructive pulmonary disease (COPD). Existing literature suggests oxidative stress from the mitochondria c driving some of the poor health outcomes in COPD. MitoQ is a mitochondrial-targeted antioxidant that has shown promise in improving cardiovascular outcomes in similar populations. Thus the purpose of this study is to test if MitoQ can improve cardiovascular health in COPD.Read full original descriptionShow less
The Influence of Mitochondrial Derived Reactive Oxygen Species on Cardiovascular Health in Patients With Chronic Obstructive Pulmonary Disease
Cardiovascular health is a critical problem in patients with chronic obstructive pulmonary disease (COPD). Existing literature suggests oxidative stress from the mitochondria c driving some of the poor health outcomes in COPD. MitoQ is a mitochondrial-targeted antioxidant that has shown promise in improving cardiovascular outcomes in similar populations. Thus the purpose of this study is to test if MitoQ can improve cardiovascular health in COPD.
Inclusion: Clinically diagnosed of COPD; Global Initiative for obstructive lung disease (GOLD) Stages II to IV.
Exclusion: Vasoactive medications; Heart Disease; Diabetes; History of coagulation; Forced Expiratory Volume in 1 second/ Functional Vital Capacity (FEV1/FVC) >0.7; Uncontrolled high blood pressure; Fluid in lungs; Sleep apnea; Raynaud's Phenomenon; Gangrene of the digits; Pregnant women; Children.